Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Elevance Health, Inc. (ELV) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Elevance Health, Inc. (ELV) lobbying for?
Summary of lobbying data for Elevance Health, Inc.:
Over the ten most recent lobbying contracts submitted by Elevance Health, Inc., they hired lobbying firms such as Tiber Creek Group, Efb Advocacy, Pllc, Alb Solutions, Tarplin, Inc., Elevance Health, Llc, Downs & Young, and Williams And Jensen to lobby government agencies including the White House Office, Agency for Healthcare Research & Quality (AHRQ), House of Representatives, Department of Treasury, Office of Management & Budget (OMB), Department of Health & Human Services (HHS), Senate, Centers For Medicare and Medicaid Services (CMS), and Department of Labor (DOL).
Elevance Health, Inc. lobbied on a range of general and specific issues. The general issue areas include taxation/internal revenue code, insurance, pharmacy, health issues, financial institutions/investments/securities, Medicare/Medicaid, and budget/appropriations. The specific issues covered long term services and supports, mental health, Dual Eligibles, Spread pricing Direct and Indirect Remuneration (DIR), Drug Rebate Rule/Executive Order, Senate Finance Committee Prescription Drug Pricing Reduction Act, Lower Drug Costs Now Act (H.R. 3), Drug Patent Reform, Robinson-Patman Reform, H.R. 5376 – Inflation Reduction Act of 2022, Pharmacy Benefit Manager Transparency Act (S. 4293), reinsurance transitional policies, ACA 1332 Waivers, individual market and exchange stabilization, prior authorization, hospital consolidation, Transparency of Hospital Billing Act (H.R.8133), Flexibility in Hospital Ownership Act, Oversight of Anti-Competitive Behavior of Non-Profit Hospitals Act, Consumer Choice of Care Act, Competition in State Healthcare Markets Act, Addressing Anti-Competitive Contracting Clauses Act, Increasing Competition for Medical Residency Act, Privacy and Healthcare Cybersecurity, Social Determinants of Health (SDOH), mental health and substance use, S.150, Medicaid Funding for Puerto Rico, Medicare Savings Program (MSP) in Medicaid, Increasing on the Medicare Advantage Benchmarks to a Minimum Level, H.R. 7997 (to Amend the SS Act to establish a floor in MA benchmark rates for regions with low Medicare fee-for-service penetration and to make the Medicare Savings Program available in all jurisdictions), H.R. 2217 (Territory Federal Matching Requirement Equity Act of 2021), H.R. 1825 (A Bill to Remove the Matching Requirement for Medicare Part D Drugs), H.R. 1826 (Fairness in Medicare Part B Enrollment Act), S. 3778 (Territories Medicare Prescription Drug Assistance Equity Act of 2022), Build Back Better Act (H.R.5376), Medicaid Eligibility and Redeterminations, Inflation Reduction Act of 2022 (H.R. 5376), Medicare Advantage Supplemental Benefits, Timely Access to Care Act (H.R. 3173 and S. 3018), 2023 Omnibus Appropriations Bill, Mental Health Parity, Restore Protections for Dialysis Patients Act (H.R.8594), H.R.959 Black Maternal Health Momnibus Act of 2021, and Helping MOMS Act of 2021.
One could infer that Elevance Health, Inc. is lobbying on these issues to influence policies that are relevant to their business and patient outcomes. For instance, their lobbying on mental health, substance use, and social determinants of health could suggest that they aim to improve access to care for individuals with these conditions, which could directly relate to their products and services. Their lobbying on Medicare, Medicaid, and insurance could also indicate that they are seeking to shape policies that could impact their revenue and market position.
